Cigarette Smoking Is Associated With Increased Human Monocyte Adhesion to Endothelial Cells: Reversibility With Oral l-Arginine but Not Vitamin C  by Adams, Mark R et al.
Cigarette Smoking Is Associated With Increased Human Monocyte
Adhesion to Endothelial Cells: Reversibility With Oral L-Arginine but
Not Vitamin C
MARK R. ADAMS, MBBS, FRACP,* WENDY JESSUP, PHD,†
DAVID S. CELERMAJER, MBBS, PHD, FRACP*†
Sydney, Australia
Objectives. This study sought to assess the effect of cigarette
smoking on adhesion of human monocytes to human endothelial
cells and to measure the effect of L-arginine and vitamin C
supplementation on this interaction.
Background. Cigarette smoking has been associated with ab-
normal endothelial function and increased leukocyte adhesion to
endothelium, both key early events in atherogenesis. Supplementa-
tion with both oral L-arginine (the physiologic substrate for nitric
oxide) and vitamin C (an aqueous phase antioxidant) may improve
endothelial function; however, their benefit in cigarette smokers is
not known.
Methods. Serum was collected from eight smokers (mean
[6SD] age 33 6 5 years) with no other coronary risk factors and
eight age- and gender-matched lifelong nonsmokers. The serum
was added to confluent monolayers of human umbilical vein
endothelial cells and incubated for 24 h. Human monocytes
obtained by counterflow centrifugation elutriation were then
added to these monolayers for 1 h, and adhesion then was
measured by light microscopy. To assess reversibility, monocyte/
endothelial cell adhesion was then measured for each subject 2 h
after 2 g of oral vitamin C and 2 h after 7 g of oral L-arginine.
Results. In smokers compared with control subjects, monocyte/
endothelial cell adhesion was increased (46.4 6 4.5% vs. 27.0 6
5.2%, p < 0.001), endothelial expression of intercellular adhesion
molecule (ICAM)-1 was increased (0.31 6 0.02 vs. 0.22 6 0.03,
p 5 0.004), and vitamin C levels were reduced (33.7 6 24.1 vs.
53.4 6 11.5 mmol/liter, p 5 0.028). After oral L-arginine, monocyte/
endothelial cell adhesion was reduced in smokers (from 46.4 6
4.5% to 35.16 4.0%, p5 0.002), as was endothelial cell expression
of ICAM-1 (from 0.31 6 0.02 to 0.27 6 0.01, p 5 0.001). After
vitamin C, there was no significant change in monocyte/
endothelial cell adhesion or ICAM-1 expression from baseline in
the smokers despite an increase in vitamin C levels (to 115 6
7 mmol/liter).
Conclusions. Cigarette smoking is associated with increased
monocyte–endothelial cell adhesion when endothelial cells are
exposed to serum from healthy young adults. This abnormality is
acutely reversible by oral L-arginine but not by vitamin C.
(J Am Coll Cardiol 1997;29:491–7)
q1997 by the American College of Cardiology
Cigarette smoking is a major risk factor for the development of
atherosclerosis, with smokers having at least a 2.5 fold increase
in the incidence of coronary heart disease compared with
nonsmokers (1). Cigarette smoke has been associated with
abnormal endothelial function in animal models of atheroscle-
rosis (2) and in young adult active and passive smokers (3,4).
Cigarette smoke also increases leukocyte adhesion to endothe-
lial cells (5,6), an important early event in atherogenesis, and is
associated with a reduction in plasma levels of vitamin C (7).
Because vitamin C is an excellent aqueous phase antioxidant in
human plasma (8), and has been shown in animal models to
slow the progression of atherosclerosis (9) and reduce leuko-
cyte aggregation (10), it has been suggested by some investi-
gators (8) that supplementation with vitamin C may be pro-
tective in smokers.
In cholesterol-fed rabbits, L-arginine, the physiologic pre-
cursor for nitric oxide, improves endothelial dysfunction, de-
creases monocyte adhesion to endothelial cells and reduces
atheroma formation (11–14). It has recently been shown that
oral and parenteral L-arginine improve endothelial function in
hypercholesterolemic humans (15–17) and may reduce platelet
aggregation in healthy young men (18). However, the effect of
L-arginine on endothelial cell/monocyte interactions in smok-
ers has not been studied. We therefore assessed the effects of
vitamin C and L-arginine supplementation on the interaction
between highly purified populations of human monocytes and
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human vascular endothelial cells exposed to serum from
smokers and nonsmokers.
Methods
Study design. Eight current smokers (lifetime dose $5
pack-years) and eight age- and gender-matched lifelong non-
smokers were studied. No subject had a history of hyperlipid-
emia or diabetes mellitus or family history of premature
coronary artery disease. All had normal blood pressure, and
the nonsmokers had no history of regular passive smoke
exposure. None of the subjects were taking regular medica-
tions, and all were clinically well. Each subject was seen on two
occasions, separated by at least 14 days. Smokers and their
matched control subjects were seen simultaneously and their
sera analyzed side by side. For each blood test, smokers were
requested to attend 10 to 30 min after their last cigarette and
were only recruited if their smoking habits were unlikely to
change over the course of the study. On each study day,
subjects had a medical and smoking history taken, blood was
drawn for baseline measurements, and either 2 g of vitamin C
(Blackmores Ltd., Balgowlah, Australia) or 7 g of L-arginine
(Scientific Hospital Supplies, Liverpool, United Kingdom) was
administered orally. Two hours after each dose, blood was taken
for analysis of treatment effect. This protocol was approved by the
local ethics committee, and all subjects gave informed consent.
At each visit, blood was collected and stored on ice in
heparinized tubes for biochemical studies (lipid measure-
ments, vitamin C, arginine, citrulline and cotinine levels) and
procoagulant-containing tubes (SST gel and clot activator
vacutainer, Becton Dickinson) for serum collection, immedi-
ately centrifuged (3,000 rpm for 10 min) at 48C and stored at
2808C until use.
Biochemical studies. Total cholesterol and triglyceride lev-
els were measured enzymatically using a Hitachi 747 autoana-
lyzer; high density lipoprotein levels were determined after
dextran sulfate magnesium precipitation; and low density
lipoprotein cholesterol levels were determined using the
method described by Friedwald et al. (19) (in no subject was
the serum triglyceride level.300 mg/dl). Arginine and vitamin
C levels were measured after deproteinizing media with 2%
sulfur salicylic acid using high performance liquid chromatog-
raphy. Plasma cotinine levels were measured using a rapid
gas–liquid chromatographic method with a nitrogen phospho-
rous detector (20).
Serum levels of inflammatory cytokines were also assessed
at baseline, after vitamin C and after L-arginine. Commercially
available enzyme-linked immunosorbent assays (ELISA) were
used to measure interleukin (IL)-1beta and interleukin (IL)-6
(Boehringer Mannheim) and to measure tumor necrosis factor
(TNF)-alpha (Genzyme Corporation).
Endothelial cell culture. Human umbilical vein endothelial
cells were harvested enzymatically, using a type II collagenase
under sterile conditions, as described by Minter et al. (21), and
established as primary cell cultures in M199 (Trace Bio-
sciences, Australia) containing 20% heat inactivated human
serum, L-glutamine 2 mmol/liter (ICN Biomedicals), 0.5%
endothelial cell growth promoter (Starrate products, Bethun-
gra, New South Wales), penicillin 100 U/ml and streptomycin
0.1 mg/ml. All media were prepared using endotoxin-free
water (Baxter, Lane Cove, Australia) and filtered using Zeta-
pore filters (Cuno Life Sciences Division). Endotoxin-free
plasticware and glassware were used in all experiments.
For experimental studies, confluent human umbilical vein
endothelial cell monolayers (passages 1 to 4) were trypsinized
and replated on gelatin-coated 24-mm diameter tissue culture
plates for monocyte adhesion studies and gelatin-coated 96-
well plates (Falcon, Becton Dickinson) for studies of cell
adhesion molecule expression. Plates were gelatin coated by
adding 1 ml/5 cm2 of Haemaccel (Behringwerke AG, Marburg,
Germany) diluted 1:250 in phosphate-buffered saline, incubat-
ing for 1 h at 378C and then decanting the solution before use.
Human umbilical vein endothelial cells were grown to conflu-
ence and used within 72 h. Before use, each monolayer was
inspected microscopically to ensure that only endothelial cells
were present, and the purity of the cultures was periodically
confirmed by staining cells using a monoclonal antibody spe-
cific for von Willebrand factor.
Isolation of human monocytes. White cell concentrate
(Red Cross Blood Bank, Sydney, Australia) was obtained from
the peripheral blood of human volunteers who had no clinical
evidence of cardiovascular disease. Monocytes were isolated
within 24 h of collection by density gradient separation of white
cell concentrate anticoagulated with 0.07% ethylenedia-
minetetraacetic acid (EDTA) (Merck Pty Ltd., Kilsyth, Aus-
tralia) on Lymphoprep (Nycomed Pharma, Oslo, Norway) at
208C followed by counterflow centrifugation elutriation, as
described by Garner et al. (22). A Beckman J2-21M/E centri-
fuge was used equipped with a JE-6B elutriation rotor and a
standard 4.2-ml elutriation chamber (Beckman Instruments,
Inc.). The elutriation buffer was Hank’s balanced salt solution
(HBSS) without calcium or magnesium (Trace Biosciences,
Australia), with EDTA (0.1 g/liter) and 1% heat inactivated
human serum added. The mononuclear cell fraction taken
from the Lymphoprep density gradient at the Lymphoprep–
plasma interface was loaded at 9 ml/min into the elutriation
rotor (2,020 rpm at 208C). The flow rate was increased by
1 ml/min every 10 min, and monocytes were eluted between 16
Abbreviations and Acronyms
EDTA 5 ethylenediaminetetraacetic acid
ELISA 5 enzyme-linked immunosorbent assay
ICAM-1 5 intercellular adhesion molecule-1
HBSS 5 Hank’s balanced salt solution
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IL-1beta 5 interleukin-1beta
IL-6 5 interleukin-6
RPMI 5 Roswell Park Memorial Institute
TNF-alpha 5 tumor necrosis factor-alpha
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and 17 ml/min. Monocyte suspensions were used only if purity
was .90% on light microscopy, with ,1% contamination by
neutrophils, and viability .95% by trypan blue exclusion.
Monocytes were then resuspended in Roswell Park Memorial
Institute (RPMI) medium containing 10% heat inactivated
human serum, penicillin (100 U/ml) and streptomycin
(0.1 mg/ml), stored in Teflon containers at a concentration
between 1.5 and 2.03 106/ml at 378C under 5% CO2 in air and
used within 3 h.
Monocyte–endothelial adhesion studies. Confluent endo-
thelial monolayers were incubated with M199 medium contain-
ing 50% serum from each subject under each condition for
24 h before adhesion assays. At the end of the 24-h incubation,
cell viability was .95% (by trypan blue exclusion) for each
condition. Experiments were repeated on at least two occa-
sions, with four separate wells used for each condition in each
subject.
Before this study, preliminary experiments were conducted
to assess the effect of varying time after elutriation and varying
incubation periods on monocyte adhesion to cultured endo-
thelial cells. These studies were carried out three times on
three separate weeks using 12 wells for each condition. In-
traobserver error was also assessed in these initial studies, with
repeated measurements taken on separate wells under the
same conditions, and repeated measurements taken on the
same wells, separated by time. Basal monocyte adhesion to
human umbilical vein endothelials (HUVECs) was not signif-
icantly different at 1 h (38%), 24 h (35%) or 48 h (35%) after
elutriation. Monocyte adhesion to HUVECs was maximal after
1-h incubation, increasing from 30 min (22%) to 1 h (38%) and
remaining unchanged at 2 h (38%). This technique had a low
intraobserver error, with a coefficient of variation ,5%.
The adhesion assay was performed by adding 1 ml of
monocyte suspension (in RPMI with 50% human serum from
the condition being tested) at a concentration of 1.0 to 1.5 3
106/ml to each endothelial cell monolayer and incubating for
1 h at 378C under 5% CO2 in air. After 1 h, nonadherent cells
were removed by standardized gentle washing using a 1,000-ml
automatic pipette (Gilson), and the suspension was stored on
ice until the cell concentration was counted using a Neubauer
hemocytometer (Weber scientific, Middlesex, United King-
dom). The initial suspensions and the suspensions from each
well were counted four times. The percentage of adherent
monocytes was then calculated by comparison with the initial
monocyte concentration.
Cell adhesion molecule detection on endothelial monolay-
ers. Endothelial cell surface expression of adhesion molecules
was assessed using an ELISA method. Confluent endothelial
monolayers were preincubated for 24 h in 96-well plates for
each subject, as previously described. After washing the mono-
layers with HBSS, monoclonal antibodies to intercellular ad-
hesion molecule (ICAM)-1, vascular cell adhesion molecule-1,
E-selectin (all Becton Dickinson) and isotype mouse immuno-
globulin G (ICN Immunobiologicals) (0.1 mg in 100 ml of
HBSS with 10% heat inactivated human serum) were added
and allowed to stand for 30 min. The monolayers were then
washed, and sheep anti-mouse–horse radish peroxidase con-
jugate (Amersham International, Amersham, UK) (1:500 in
100 ml of HBSS with 10% heat inactivated human serum and
0.05% Tween 20) was added and left for 30 min. After further
washing, 150 ml of ABTS [2,29-azino-di(3-ethylbenzothiazoline
sulfonate)] substrate (Kirkegaard and Perry Laboratories) was
added to each well and allowed to develop for 15 min. Optical
density was measured at 414 nm with an ELISA reader
(Titertek multiscan, Flow Laboratories, Meckenheim, Fin-
land).
Statistics. Data were analyzed with SPSS for Windows 6.0.
All descriptive data are expressed as mean value 6 SD.
Differences between smokers and nonsmokers were assessed
using independent sample t tests, adjusted for multiple com-
parisons using Hochberg’s modification of the Bonferroni
procedure (23). Differences between baseline, vitamin C and
L-arginine were assessed using repeated measures analysis of
variance, followed by the Scheffe´ procedure for multiple
comparisons. Statistical significance was inferred at a two-
tailed p value , 0.05.
Results
The baseline characteristics of the subjects are summarized
in Table 1. Smokers had a higher level of plasma cotinine than
nonsmokers (p , 0.001). Cotinine levels in the smokers were
similar on each blood collection, consistent with a stable
pattern of cigarette exposure. Vitamin C levels were signifi-
cantly reduced in smokers compared with nonsmokers (33.7 6
24.1 versus 53.4 6 11.5 mmol/liter, p 5 0.028). Other baseline
characteristics, such as age and lipid and L-arginine levels, were
not different between the two groups. Both vitamin C and
L-arginine supplementation were well tolerated, although one
subject complained of a mild headache after L-arginine admin-
istration. After vitamin C administration, serum vitamin C
levels rose significantly in both smokers (from 33.7 6 24.1 to
115.8 6 40.3 mmol/liter, p , 0.001) and nonsmokers (from
52.4 6 11.5 to 133.4 6 47.5 mmol/liter, p , 0.001). Vitamin C
levels rose to at least normal levels in all subjects after







Age (yr) 336 5 31 6 4 0.44
Cigarettes/day 26 6 7 0.0 , 0.001
Pack-yr 14 6 4 0.0 , 0.001
Cotinine (nmol/liter) 2,2116 1,092 33 6 92 , 0.001
Total cholesterol (mg/dl) 178.96 19.5 198.4 6 31.1 0.21
Triglycerides (mg/dl) 87.36 35.3 88.2 6 26.5 0.90
LDL cholesterol (mg/dl) 112.86 19.5 132.3 6 35.0 0.15
HDL cholesterol (mg/dl) 50.66 11.7 54.5 6 15.6 0.70
Vitamin C (mmol/liter) 33.7 6 24.1 53.4 6 11.5 0.028
L-Arginine (mmol/liter) 128.5 6 30.0 147.7 6 43.1 0.33
*Groups are compared using independent sample t tests with Hochberg’s
modification of the Bonferroni procedure (see Methods). HDL 5 high density
lipoprotein; LDL 5 low density lipoprotein.
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supplementation (range 66.0 to 190.0 mmol/liter in smokers
and 58.0 to 176.0 mmol/liter in nonsmokers). After L-arginine,
arginine levels rose significantly in both smokers (from 128.56
29.9 to 294.9 6 63.9 mmol/liter, p 5 0.005) and in nonsmokers
(from 147.7 6 43.1 to 235.7 6 25.0 mmol/liter, p , 0.01).
Citrulline levels were similar in both groups at baseline (26.06
7.1 mmol/liter in smokers, 23.1 6 2.2 mmol/liter in nonsmok-
ers) and did not change with L-arginine supplementation.
There was no difference in serum cytokine levels at baseline
between smokers and nonsmokers (IL-1beta: 25.6 6 19.9 pg/ml
in nonsmokers, 32.7 6 15.2 pg/ml in smokers, p 5 0.13; IL-6:
10.4 6 6.6 pg/ml in nonsmokers, 12.75 6 5.9 pg/ml in smokers,
p 5 0.45; TNF-alpha: 27.8 6 18.3 pg/ml in nonsmokers, and
33.8 6 17.4 pg/ml in smokers, p 5 0.5). None of the measured
cytokines changed significantly in smokers or nonsmokers after
either vitamin C or L-arginine (data not shown).
Cigarette smoking is associated with increased monocyte
adhesion to endothelial cells. Monocyte adhesion to endothe-
lial cells exposed to serum from smokers was significantly
higher than adhesion to endothelial cells exposed to serum
from nonsmokers (46.4 6 4.5% vs. 27.0 6 5.2%, p , 0.001), as
illustrated in Figure 1.
Increased monocyte adhesion to endothelial cells is associ-
ated with increased surface expression of ICAM-1. Surface
expression of ICAM-1 on human umbilical vein endothelial
cells was higher in cell monolayers exposed to serum from
smokers than in those from nonsmokers (optical density:
0.31 6 0.02 vs. 0.22 6 0.03, p 5 0.004) (Table 2). However, no
difference was seen in the surface expression of vascular cell
adhesion molecule (VCAM)-1 (optical density: 0.13 6 0.02 in
smokers vs. 0.11 6 0.01 in nonsmokers, p 5 NS) or E-selectin
(optical density: 0.19 6 0.03 in smokers vs. 0.20 6 0.01 in
nonsmokers, p 5 NS).
L-Arginine but not vitamin C supplementation reduces
monocyte adhesion to endothelial cells. Monocyte adhesion to
endothelial cells exposed to serum from smokers was reduced
when the endothelial cells were exposed to serum taken from
the same smokers after oral L-arginine supplementation (from
46.4 6 4.1% to 35.1 6 4.0%, p 5 0.002) (Fig. 2). However, no
change was seen in nonsmokers after L-arginine supplementa-
tion (26.9 6 5.1% to 27.6 6 5.5%, p 5 NS). After vitamin C
supplementation, there was no significant change in the degree
of monocyte adhesion to endothelial cell monolayers in either
smokers (46.46 4.5% to 41.96 8.5%, p5 NS) or nonsmokers
(27.0 6 5.2% to 26.8 6 5.6%, p 5 NS).
There was no associated change in the surface expression of
either VCAM-1 or E-selectin after exposure of the endothelial
monolayers to serum from subjects after vitamin C or
Figure 1. Photomicrographs showing monocyte adhe-
sion to HUVEC monolayers, randomly taken from the
center of 25-mm wells. The monolayer on the left
(smoker) has been incubated for 24 h with media
containing 50% serum from a smoker before the
adhesion study. The monolayer on the right (non-
smoker) has been incubated for 24 h in media contain-
ing 50% serum taken from a nonsmoker.








Monocyte adhesion (%) 46.4 6 4.4 26.9 6 5.1 0.001
ICAM-1 (optical density) 0.31 6 0.02 0.22 6 0.03 0.004
VCAM-1 (optical density) 0.13 6 0.02 0.11 6 0.01 0.21
E-selectin (optical density) 0.19 6 0.03 0.20 6 0.01 0.64
*Groups are compared using independent sample t tests with Hochberg’s
modification of the Bonferroni procedure (see Methods). ICAM-1 5 intercel-
lular adhesion molecule-1; VCAM-1 5 vascular cell adhesion molecule-1.
Figure 2. Effect of L-arginine and vitamin C on monocyte adhesion to
human umbilical vein endothelial cell monolayers. Error bars repre-
sent standard error of the mean. Levels of monocyte adhesion in
nonsmokers are lower than those in smokers at baseline (p 5 0.001).
The level of monocyte adhesion to endothelial cells in smokers was
reduced after L-arginine administration (p 5 0.002) but not after
vitamin C (p 5 NS). All groups were compared by repeated measures
analysis of variance, followed by the Scheffe test for multiple compar-
isons.
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L-arginine. However, there was a small reduction in ICAM-1
expression in smokers after L-arginine supplementation (from
0.31 6 0.02 to 0.27 6 0.01, p 5 0.001), consistent with the
reduction seen in monocyte adhesion to endothelial cells.
Discussion
Monocyte adhesion to endothelium is a key early event in
atherogenesis, preceding monocyte entry into the subintima,
transformation into macrophages, lipid loading and fatty
streak formation (24). Even in the first decades of life,
cigarette smokers exhibit greater fatty streak and atheroma
formation than nonsmokers (25). In the present study, we
showed that cigarette smoking is strongly associated with
increased monocyte adhesion to endothelium and that serum
from smokers induces greater endothelial cell expression of
ICAM-1 than that from control subjects. Furthermore, the
smoke-related increase in monocyte/endothelial adhesion was
almost completely reversed by the administration of a single
oral dose of L-arginine, the physiologic precursor of nitric
oxide (26) and associated with decreased surface expression of
ICAM-1. In contrast, a single dose of vitamin C did not affect
the degree of adhesion, in this model.
Smoking and atherosclerosis. The mechanism of acceler-
ated atherogenesis in relation to smoking is unknown; how-
ever, both animal (27) and human studies (28) have confirmed
a continuous and graded relation between smoke exposure and
atherosclerosis. Cigarette smoke contains thousands of chem-
ical compounds (29) that may affect both the arterial wall or
circulating blood components, thus increasing the risk of
clinical cardiovascular disease. For example, smokers have
abnormal platelet aggregation (30), abnormalities of circulat-
ing blood leukocytes (6,31), increased fibrinogen levels (32)
and enhanced thrombin generation (33). All of these may
contribute to both atherosclerosis and thrombosis.
Smoking, endothelium and nitric oxide. Tobacco has a
direct toxic effect on human endothelium (34,35). Such injury
to the arterial wall may be particularly important in precipi-
tating the cellular events of atherogenesis (24). In vitro, it has
been shown that serum from smokers is directly cytotoxic to
cultured endothelial cells (36). In vivo, we previously showed
that endothelium-dependent dilation, a nitric oxide-dependent
phenomenon (37), is markedly impaired in young adult smok-
ers (3). It is also known that endothelial release of nitric oxide
is important in the control of intercellular adhesion molecule
expression, through a nuclear factor-kB–dependent pathway
(38). In the current study, inflammatory cytokine levels were
not different in smokers and nonsmokers, suggesting that these
changes in endothelial function may not be mediated by
alterations in cytokine levels. Similarly, Anderson et al. (39)
previously reported changes in neutrophil activity of passive
smokers that was not associated with alterations in cytokine
levels. Although the regulation of cell adhesion molecules is
complex, the cigarette smoke-related enhancement of mono-
cyte/endothelial adhesion in this study may be due (at least in
part) to impaired endothelial nitric oxide release, with conse-
quent increased expression of intercellular adhesion mole-
cules. In this context, it is interesting that a single oral dose of
L-arginine, the nitric oxide precursor, was able to decrease
significantly the monocyte adhesion to endothelium in smok-
ers, and that this was associated with decreased endothelial
expression of ICAM-1.
L-Arginine has previously been shown to have important
antiatherogenic effects, both in animals (11–14) and in humans
(15–18). In hypercholesterolemic rabbits, oral L-arginine may
reduce atheroma formation (11), decrease cholesterol-related
endothelial dysfunction, reduce platelet aggregation and de-
crease monocyte adhesion to aortic endothelium (11–14). In
humans, both acute parenteral and longer term oral therapy
with L-arginine improves endothelium-dependent dilation in
hypercholesterolemic young adults (15,16), and oral L-arginine
has recently been shown (18) to inhibit platelet aggregation in
healthy young men through the nitric oxide pathway. There
have been no previous reports of the effects of L-arginine in
smokers or of L-arginine’s effects on monocyte/endothelial
interactions in humans. However, L-arginine does appear to
improve endothelium-dependent dilation in smoke-exposed,
cholesterol-fed rabbits (40). The mechanism of the beneficial
effect of L-arginine in smokers may be related to enhanced
endothelial production of nitric oxide, an antioxidant effect of
L-arginine, which may decrease nitric oxide catabolism by
smoke-enhanced oxygen-derived free radicals (41), or other
mechanisms.
Smoking, monocytes and vitamin C. The important inter-
action between monocytes and the endothelium is complex and
may also be affected by monocytes as well as a variety of
biochemical factors (42). It has been shown (10) in animal
models, using an intravital microscopic technique, that ciga-
rette smoke increases leukocyte aggregation and adhesion to
endothelial cells in vivo. In vitro studies of human cells have
also documented this increase in monocyte/endothelial cell
adhesion (6). Kalra et al. (5) observed changes in both
circulating monocytes and in cultured endothelial cells when
exposed to cigarette smoke; in particular, they noted an
increase in the expression of CD11b ligand on the surface of
monocytes as well as an increase in endothelial expression of
ICAM-1 and E-selectin. Weber et al. (31) recently demon-
strated an enhanced expression of the integrin CD11b/CD18
on monocytes isolated from smokers and that this was associ-
ated with increased adhesiveness to cultured endothelial cells.
Other circulating factors such as platelet activating factor-like
lipids may also play a role in modifying the monocyte/
endothelial cell interaction (43). Due to the complexity of
monocyte/endothelial interactions, interventions aimed at re-
ducing atherogenesis in cigarette smokers may need to address
smoke-induced changes in both monocyte as well as endothe-
lial factors.
Vitamin C has been proposed by some investigators as a
potentially protective agent in smokers due to its antioxidant
properties (8), particularly because cigarette smoke is an
important source of circulating reactive oxygen intermediates
(44). Vitamin C levels are significantly decreased in smokers
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(7,45). In the study by Weber et al. (31), 10 days of vitamin C
reversed the smoke-related increase in monocyte expression of
CD11b/CD18 and returned monocyte adhesion to unstimu-
lated endothelial cells toward normal (although there was no
effect on adhesion to stimulated endothelial cells, as are
usually found at sites of atherosclerosis) (46). This is consistent
with some in vitro work, where vitamin C has been shown (10)
to reduce leukocyte/endothelial adhesion during oxidized low
density lipoprotein exposure and in vivo animal studies dem-
onstrating reduced leukocyte adhesion with acute parenteral
administration of vitamin C. However, in our model, oral
vitamin C consistently failed to influence human monocyte to
human endothelial cell adhesion in either smokers or non-
smokers, despite an increase in serum vitamin C levels to .50
to 60 mmol/liter in all subjects (which is above the estimated
threshold for effective protection from cardiovascular disease)
(47). It may be that prolonged elevation in vitamin C levels
may be required for benefit in humans rather than simply high
circulating vitamin C levels in the blood stream, although a
single oral dose of vitamin C may improve endothelial function
in patients with coronary artery disease (48). Possibly, the
optimal strategy for normalizing monocyte/endothelial adhe-
sion in smokers involves decreasing endothelial as well as
monocyte adhesiveness, for example, by a combination of
L-arginine and vitamin C.
Study limitations. Although our subjects were well matched
for age, gender and the absence of other vascular risk factors
apart from smoking, it is possible that there were unmeasured
differences between the smokers and nonsmokers that might
account for the observed increase in monocyte/endothelial
adhesion seen in the smokers. Because monocyte/endothelial
adhesion would be very difficult to study in vivo in humans, we
used a model of monocyte/endothelial cell adhesion that is
accurate and reproducible and utilizes highly purified popula-
tions of human cells only. Despite this, the ex vivo model used
in this and other (31) studies may not accurately reflect the in
vivo situation. For example, human venous endothelial cells do
not usually express adhesion molecules; the endothelial cells in
our model did express such molecules, which may actually be
analagous to the situation in arterial endothelial cells in vivo
(49). It is also possible that some of the components of
cigarette smoke in human serum may have been altered or
metabolized during the 24-h incubation times in culture,
especially because many are labile (29); despite this, our results
are consistent with other models, where increased monocyte/
endothelial adhesion has consistently been found in associa-
tion with cigarette smoking. Other ex vivo experiments (31)
have used isolated monocytes from smokers, rather than using
serum, to study monocyte/endothelial adhesion. Because hu-
man serum is complex and contains factors that may both
increase and decrease monocyte/endothelial cell adhesion (50),
the use of isolated human cells without serum may not reflect
the in vivo situation. For example, the presence of soluble cell
adhesion molecules may alter monocyte/endothelial cell inter-
actions. For this reason, we utilized a model where complete
serum from each subject is incubated with endothelial cells
before monocyte adhesion was assessed. The model used in
our study primarily assesses the effect of L-arginine and vitamin
C on endothelial adhesiveness and does not look at possible
differences between the monocytes of individual subjects or the
effect of vitamin C and L-arginine on monocyte physiology.
Clinical implications. Because monocyte adhesion to en-
dothelial cells is a key early event in atherogenesis and appears
to be enhanced in young healthy adult smokers, this empha-
sizes that smoking at an early age can damage the arterial wall.
This is consistent with both the physiologic evidence of endo-
thelial damage that we previously observed in young smokers
(3,4) and with the fatty streak formation seen even in teenage
smokers (25). Intervention aimed at an early stage of the
atherogenic process maximizes the chances of reversibility of
arterial disease (51). Clearly, prevention of smoking by young
adults would be the optimal strategy, or cessation in those who
already smoke (although it is not established that smoking
cessation would reverse the enhanced monocyte/endothelial
adhesion observed in this and other studies). However, where
these strategies are not successful, intervention with L-arginine
may be a promising therapy because it is a naturally occurring
substance with an excellent safety profile (18). Nevertheless,
long-term efficacy needs to be proved. On the basis of work to
date, a synergistic beneficial effect with oral vitamin C may also
be possible.
Conclusions. Cigarette smoking is associated with in-
creased monocyte adhesion to endothelial cells, a key early
event in atherosclerosis. This is associated with increased
expression of ICAM-1 and decreased plasma levels of vitamin
C. In our study, oral L-arginine but not vitamin C supplemen-
tation was associated with a reduction of monocyte/endothelial
cell adhesion in smokers. Whether L-arginine will prove useful
as a protective agent in smokers requires further prospective
evaluation.
We are indebted to Andrew Brown, PhD, and David Sullivan, FRACP for their
expert advice and Mandy Edwards for excellent technical assistance.
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